Loading cancer entity…
Loading cancer entity…
Clinical trials
4,036 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (701)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04156256 | CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | unknown | Early Phase 1 | 20 | iCell Gene TherapeuticsINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT03291353 | Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia | withdrawn | Early Phase 1 | 0 | Michael BoyiadzisOTHER | 1 | Apr 19, 2019 | clinicaltrials |
| NCT03228303 |
| Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia |
| unknown |
| Early Phase 1 |
| 100 |
| Assiut UniversityOTHER |
| 0 |
| Oct 10, 2017 |
| clinicaltrials |
| NCT02805868 | Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis | withdrawn | Early Phase 1 | 0 | Northwestern UniversityOTHER | 0 | Oct 24, 2016 | clinicaltrials |
| NCT00437086 | Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders | completed | Early Phase 1 | 30 | Mayo ClinicOTHER | 1 | Oct 17, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Nov 12, 2019source: clinicaltrials